Amicus Therapeutics Share Price Nasdaq
Equities
Biotechnology & Medical Research
Sales 2024 * | 529M 44.09B | Sales 2025 * | 681M 56.75B | Capitalization | 3.08B 257B |
---|---|---|---|---|---|
Net income 2024 * | -1M -83.36M | Net income 2025 * | 120M 10B | EV / Sales 2024 * | 6.09 x |
Net Debt 2024 * | 139M 11.59B | Net Debt 2025 * | 24.31M 2.03B | EV / Sales 2025 * | 4.56 x |
P/E ratio 2024 * |
-1,713
x | P/E ratio 2025 * |
26.8
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.81% |
Latest transcript on Amicus Therapeutics
Managers | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 01/06/01 |
Simon Harford
DFI | Director of Finance/CFO | 64 | 21/23/21 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 48 | 01/06/01 |
Lynn Bleil
BRD | Director/Board Member | 60 | 11/18/11 |
Burke W. Whitman
BRD | Director/Board Member | 68 | 27/19/27 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |